Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash & Equivalents (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Cash & Equivalents for 5 consecutive years, with $1.2 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 36.84% year-over-year to $1.2 billion, compared with a TTM value of $1.2 billion through Sep 2025, down 36.84%, and an annual FY2025 reading of $2.7 billion, down 58.19% over the prior year.
  • Cash & Equivalents was $1.2 billion for Q3 2025 at Roivant Sciences, up from $94.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $6.7 billion in Q4 2023 and bottomed at $94.8 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $2.5 billion, with a median of $2.0 billion recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 336.73% in 2023, then tumbled 98.34% in 2025.
  • Year by year, Cash & Equivalents stood at $2.2 billion in 2021, then plummeted by 30.57% to $1.5 billion in 2022, then soared by 336.73% to $6.7 billion in 2023, then plummeted by 70.16% to $2.0 billion in 2024, then tumbled by 37.86% to $1.2 billion in 2025.
  • Business Quant data shows Cash & Equivalents for ROIV at $1.2 billion in Q3 2025, $94.8 million in Q2 2025, and $2.7 billion in Q1 2025.